Loading company
Just reported
Q2 FY2027 results
From Canopy Growth's results release of November 6, 2026; its quarterly report has since been filed.
Revenue
Actual
$81.4M
+22% y/y
+0.3% q/qGuided
—
No guide given
EPS, GAAP
Actual
-$0.10
Guided
—
No guide given
Operating income, GAAP
Actual
-$23M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Canopy Growth is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$33.5BA
NBIXNeurocrine Biosciences, Inc.$17.6BA+
ELANElanco Animal Health Incorporated$13.2BA
KNSAKiniksa Pharmaceuticals International, plc$8.1BA+
LQDALiquidia Corporation$5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now A
Built from Canopy Growth Corporation’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This company files in CAD. Figures are converted to US dollars at $1.00 = 1.4249 CAD, the current rate, applied to every period alike — so growth and margins are the company’s own and not the exchange rate’s. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
